Online citations, reference lists, and bibliographies.
← Back to Search

Toward The Establishment Of Standardized In Vitro Tests For Lipid-based Formulations, Part 4: Proposing A New Lipid Formulation Performance Classification System.

H. Williams, P. Sassene, Karen Kleberg, Marilyn Calderone, A. Igonin, Eduardo Jule, J. Vertommen, Ross D. Blundell, H. Benameur, A. Müllertz, C. H. Porter, C. Pouton
Published 2014 · Computer Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading.
This paper references
10.1002/jps.21451
Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption.
Ping Gao (2009)
10.1211/jpp.62.01.0006
Effects of polysorbate 80 on the in‐vitro precipitation and oral bioavailability of halofantrine from polyethylene glycol 400 formulations in rats
H. Tønsberg (2010)
10.1023/B:PHAM.0000036914.22132.cc
Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation
C. H. Porter (2004)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1016/j.ejps.2013.04.036
In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
R. Devraj (2013)
10.1002/jps.21502
Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states.
S. Clarysse (2009)
10.1002/jps.22217
The developability classification system: application of biopharmaceutics concepts to formulation development.
J. Butler (2010)
10.1211/jpp.58.8.0009
Characterization of fasted‐state human intestinal fluids collected from duodenum and jejunum
Mariangeles Perez de la Cruz Moreno (2006)
10.1002/jps.23856
Choice of nonionic surfactant used to formulate type IIIA self-emulsifying drug delivery systems and the physicochemical properties of the drug have a pronounced influence on the degree of drug supersaturation that develops during in vitro digestion.
R. Devraj (2014)
10.1007/s11095-013-1038-z
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations
H. Williams (2013)
10.1007/s11095-007-9363-8
Low Dose Lipid Formulations: Effects on Gastric Emptying and Biliary Secretion
Greg A Kossena (2007)
10.1208/s12248-014-9672-x
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels
P. Sassene (2014)
10.1021/mp3006566
Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.
Yan Yan Yeap (2013)
10.1002/JPS.21246
Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
Jean F Cuiné (2008)
10.1124/PR.112.005660
Strategies to Address Low Drug Solubility in Discovery and Development
H. Williams (2013)
10.1002/JPS.10511
Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability.
Ping Gao (2003)
10.1016/J.EJPS.2006.04.016
Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system.
C. Pouton (2006)
10.1007/s11095-005-8476-1
Characterization of the Human Upper Gastrointestinal Contents Under Conditions Simulating Bioavailability/Bioequivalence Studies
L. Kalantzi (2005)
10.1021/JM3006433
Application of lipid-based formulations in drug discovery.
X. Chen (2012)
10.1016/0166-6622(87)80207-X
Bile salts as biological surfactants
A. Hofmann (1987)
10.1016/J.ADDR.2007.10.010
Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
C. Pouton (2008)
10.1002/jps.22122
Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity.
Karen Kleberg (2010)
10.1007/s11095-006-9194-z
Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs
Jean F Cuiné (2006)
10.1021/mp300331z
Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
H. Williams (2012)
10.1021/mp300164u
Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.
M. U. Anby (2012)
10.1016/j.ejpb.2013.10.016
Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate.
B. Griffin (2014)
10.1016/J.BBALIP.2007.02.009
Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol, medium chain glycerides and PEG esters.
S. Fernandez (2007)
10.1517/17425247.3.1.97
Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs
Ping Gao (2006)
10.1016/j.ejps.2010.07.005
Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes.
Anne Christiansen (2010)
10.1002/jps.21659
Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.
K. Mohsin (2009)
10.1016/J.IJPHARM.2007.08.057
Stable drug encapsulation in micelles and microemulsions.
A. Narang (2007)
10.1021/mp400035z
The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs.
Yan Yan Yeap (2013)
10.1002/JPS.20039
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
C. H. Porter (2004)
10.1002/jps.23205
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.
H. Williams (2012)
10.1146/ANNUREV.ME.18.020167.002001
Detergent properties of bile salts: correlation with physiological function.
A. Hofmann (1967)
10.1007/s11095-013-1126-0
Lipid-Based Formulations and Drug Supersaturation: Harnessing the Unique Benefits of the Lipid Digestion/Absorption Pathway
H. Williams (2013)



This paper is referenced by
Bio-relevant characterisation of lipidic formulations and prediction of in vivo exposure
Paloma Benito-Gallo (2017)
10.1016/j.ijpharm.2016.09.032
The gut in the beaker: Missing the surfactants?
C. Wilson (2016)
10.1002/9781118675748.ch1
Lipid‐Based Oral Formulations
M. Kılıç (2019)
10.1016/j.biochi.2015.11.016
Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs.
F. Carrière (2016)
10.1016/j.ijpharm.2017.12.032
Size characterization of lipid-based self-emulsifying pharmaceutical excipients during lipolysis using Taylor dispersion analysis with fluorescence detection.
J. Chamieh (2018)
10.1016/j.addr.2019.06.010
In vitro digestion models to evaluate lipid based drug delivery systems; present status and current trends.
R. Berthelsen (2019)
10.3390/pharmaceutics12010017
Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure
Erin Tay (2019)
10.19080/CTBEB.2018.13.555867
Self-Micro-Emulsifying Drug Delivery System to Enhance the Solubility of the Hydrophobic Drugs
Shastri Divyesh (2018)
10.1016/j.ejpb.2017.11.003
Measuring the emulsification dynamics and stability of self‐emulsifying drug delivery systems
Teófilo Vasconcelos (2018)
10.1021/acs.molpharmaceut.7b00442
Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies.
Yasemin Şahbaz (2017)
10.1208/s12249-017-0785-2
Self-emulsification of Lipidic Drug Delivery System in Pure Water and in Concentrated Glycerol Solution
C. Planchette (2017)
10.1016/j.ijpharm.2016.04.044
Impact of lipases on the protective effect of SEDDS for incorporated peptide drugs towards intestinal peptidases.
G. Leonavičiūtė (2016)
10.1201/9781315364537-6
The Modern Pharmaceutical Development Challenge: BCS Class II and IV Drugs
Gregory K. Webster (2017)
10.1016/j.ejpb.2017.03.001
Opening NADPH oxidase inhibitors for in vivo translation
Nina Hecht (2017)
10.1016/j.addr.2019.01.009
Bridging the gaps between academic research and industrial product developments of lipid-based formulations.
R. Holm (2019)
10.1016/j.addr.2016.04.007
50years of oral lipid-based formulations: Provenance, progress and future perspectives.
O. Feeney (2016)
10.3390/pharmaceutics12040365
Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems
Heejun Park (2020)
10.1016/j.ijpharm.2016.09.032
The gut in the beaker: Missing the surfactants?
C. Wilson (2016)
10.1016/j.jconrel.2016.02.001
Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
Kevin Pham (2016)
10.1016/j.ejpb.2015.07.014
Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments.
J. O'Shea (2015)
10.3109/03639045.2014.972412
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract
V. Jannin (2015)
10.1016/j.ijpharm.2015.09.009
Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity.
V. Jannin (2015)
10.1016/j.jconrel.2014.07.037
'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
O. Feeney (2014)
10.1021/ACS.MOLPHARMACEUT.6B00597
Linking in Vitro Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations.
Paloma Benito-Gallo (2016)
10.1016/j.addr.2019.05.008
Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.
H. Williams (2019)
10.1007/978-3-319-42609-9_7
Lipid-Based Formulations
Justin S. Lafountaine (2016)
10.1016/j.ejps.2019.104967
Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems.
B. Boyd (2019)
10.1517/17425247.2016.1151872
Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery
Shasha Rao (2016)
10.1007/s11095-015-1843-7
A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations
Matthew F. Crum (2015)
10.1021/acs.molpharmaceut.7b00660
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
Claire L McEvoy (2017)
Mechanistic understanding of bioenabling formulation approaches to improve oral bioavailability using porcine in vivo and in silico models
Joseph P. O'Shea (2018)
10.1039/C6FO00158K
Comparison of lipases for in vitro models of gastric digestion: lipolysis using two infant formulas as model substrates.
P. Sassene (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar